A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT04576988
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 324 participants
- Registry
-
NCT04576988 -
2020-004142-11
-
- Main results
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Serbia, South Korea, Spain, Sweden, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04576988. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-25 (actual); primary completion 2022-08-26 (actual). Results posted on 2023-08-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Biological)
- Sotatercept
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Background PAH Therapy
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Record details
- Record id
cardio:ct-nct04576988- Content hash
f684fb72643c132bb6442306875043701ee33f233b51bef012199e3a5bf85eef